Related Experiment Video
Updated: Jul 7, 2026
Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
Published on: February 20, 2017
KLK8: charting new territories in left ventricular hypertrophy biomarker research
Buqing Cao1, Wenhong Yu1, Zhihong Diao1
1Department of Laboratory Medicine, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China.
Insights
Serum Kallikrein-related peptidase 8 (KLK8) shows promise as a biomarker for detecting left ventricular hypertrophy (LVH) in hypertensive patients. Higher KLK8 levels were observed in patients with LVH, indicating its diagnostic potential.
Area of Science:
- Biochemistry
- Cardiology
- Biomarker Discovery
Background:
- Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular events in hypertensive individuals.
- Early detection of LVH is crucial for timely intervention and improved patient outcomes.
- Novel biomarkers are needed to enhance the diagnostic capabilities for LVH in hypertension.
Purpose of the Study:
- To investigate the diagnostic potential of serum Kallikrein-related peptidase 8 (KLK8) for detecting left ventricular hypertrophy (LVH).
- To evaluate the association between serum KLK8 levels and the presence of LVH in hypertensive patients.
Main Methods:
- Serum KLK8 levels were measured using ELISA in 62 hypertensive patients with LVH, 60 hypertensive patients without LVH, and 60 healthy controls.
- Left ventricular hypertrophy (LVH) was diagnosed via echocardiography based on LVMI thresholds.
- Receiver operating characteristic (ROC) curve analysis was employed to assess the diagnostic performance of KLK8.
Main Results:
- Serum KLK8 levels were significantly elevated in hypertensive patients with LVH compared to those without LVH and healthy controls.
- KLK8 levels demonstrated a positive correlation with blood pressure and cardiac structural parameters (IVST, LVPWT, LVEDD).
- ROC analysis indicated high sensitivity and specificity for KLK8 in detecting LVH.
Conclusions:
- Serum KLK8 possesses significant diagnostic value for predicting left ventricular hypertrophy (LVH) in hypertensive patients.
- KLK8 may serve as a potential non-invasive biomarker for early LVH detection in the context of hypertension.
Objective:
This study investigates the diagnostic potential of serum Kallikrein-related peptidase 8 (KLK8) in detecting left ventricular hypertrophy (LVH).
Methods:
A total of 62 hypertensive patients with LVH, 60 without LVH, and 60 healthy controls were analyzed. LVH was defined by echocardiography using LVMI thresholds (>95 g/m2 for females, >115 g/m2 for males). Serum KLK8 levels were measured via ELISA, and receiver operating characteristic (ROC) curve analysis assessed its diagnostic performance.
Results:
KLK8 levels were significantly higher in hypertensive patients with LVH (8.59 ± 1.59 ng/mL) than in those without LVH (5.80 ± 1.35 ng/mL) and healthy controls (3.68 ± 0.82 ng/mL). KLK8 positively correlated with blood pressure and cardiac structural parameters, including IVST, LVPWT, and LVEDD. ROC analysis revealed high sensitivity and specificity, indicating KLK8's potential as a biomarker for early LVH detection in hypertension.
Conclusion:
In hypertensive patients, KLK8 demonstrates good diagnostic value in predicting LVH.
